Maltose modified poly(propylene imine) dendrimers as potential carriers of nucleoside analog 5′-triphosphates.

Szulc, Agata; Signorelli, Marco; Schiraldi, Alberto; Appelhans, Dietmar; Voit, Brigitte; Bryszewska, Maria; Klajnert‐Maculewicz, Barbara; Fessas, Dimitrios

doi:10.1016/j.ijpharm.2015.09.065

Cited by 28 publications

(27 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, maltose residues were attached at the amino terminal group of poly(propylene imine). Cytarabine triphosphate was then mixed with dendrimer in phosphate buffer saline, and a complex was finally obtained as a result of ionic interactions between the negatively charged cytarabine and the cationic dendrimer [89]. Cytarabine triphosphate-complexed dendrimers did not significantly decrease HL-60 cell viability compared with cytarabine in solution.…”

Section: Nanoparticles Based On Polymersmentioning

confidence: 99%

Advances in treatment formulations for acute myeloid leukemia

Briot

Roger

Thépot

et al. 2018

Drug Discovery Today

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is the most common cause of leukemia-related mortality. The combination of cytarabine and anthracycline has been the gold standard of treatment over the past 40 years, but the distribution of the drugs in the body leads to severe adverse effects. Poor prognosis of older patients with AML is the consequence not only of comorbidities, but also of chemoresistance resulting from frequent secondary AML. Numerous strategies using nanotechnologies are in development to improve drug targeting, pharmacokinetics, administration route, chemoresistance, and adverse effects generally observed. Among the four new drugs approved for AML by the US Food and Drug Administration (FDA) in 2017, Vyxeos is a novel liposomal formulation of historical AML drugs. Here, we review current AML treatments and discuss how the development of new formulations will change the therapeutic armamentarium.

show abstract

Section: Nanoparticles Based On Polymersmentioning

confidence: 99%

Advances in treatment formulations for acute myeloid leukemia

Briot

Roger

Thépot

et al. 2018

Drug Discovery Today

View full text Add to dashboard Cite

show abstract

“…Our scientific interests have concentrated on the possibility of using so‐called open‐shell (OS) poly(propyleneimine) (PPI) dendrimers with their surfaces partially coated with maltose units for the intracellular delivery of active triphosphate forms of adenosine analogues. Such glycodendrimers exhibit high biocompatibility as well as the capacity to form stable complexes with nucleoside triphosphates and to protect them from enzymatic degradation . We proved that the fourth generation maltose‐modified PPI dendrimer (PPI‐Mal OS G4) can serve as an efficient nanocarrier for an active metabolite of fludarabine (Ara‐FATP), increasing its cytotoxic activity and overcoming NT‐associated resistance due to the independent mechanism of cell entry …”

Section: Zeta Potential Of Ppi Dendrimers and Nucleotide–dendrimer Comentioning

confidence: 98%

Effect of the Structure of Therapeutic Adenosine Analogues on Stability and Surface Electrostatic Potential of their Complexes with Poly(propyleneimine) Dendrimers

Gorzkiewicz

Appelhans

Boye

et al. 2019

Macromol. Rapid Commun.

Self Cite

View full text Add to dashboard Cite

Poly(propyleneimine) glycodendrimers are proposed as nanocarriers for triphosphate forms of anticancer adenosine analogues to improve the efficiency of chemotherapy and to overcome drug resistance mechanisms. This approach has proven successful for fludarabine administration—an autonomous way of cellular entry of a nucleotide–dendrimer noncovalent complex enables an increase in the intracellular accumulation and cytotoxic activity of the active metabolite of the drug. However, the attempt to apply an analogous strategy for clofarabine results in the inhibition of drug activity. To better understand this phenomenon, characterization and comparison of drug‐dendrimer complexes were needed to indicate the differences in their surface properties and the strengths of fludarabine‐dendrimer and clofarabine‐dendrimer interactions. Here, zeta potential measurements, ultrafiltration, and asymmetric flow field‐flow fractionation are applied to determine the surface electrostatic potential and stability of nucleotide–dendrimer formulations. This approach significantly extends the authors’ research on the complexation potential of perfectly branched macromolecules, ultimately explaining previously observed differences and their consequences.

show abstract

“…These dendrimers have been chosen owing to their biopermeability, non-toxicity, non-immunogenicity and ability to stay in the blood circulation. [122][123][124][125][126] Also worth mentioning is the research of M. Gorzkiewicz and coworkers, where dendrimers served as nano-carriers for udarabine, while simultaneously improving its cellular entry and enabling both the direct and phosphorylation-independent toxicity. 127 5.1.2.…”

Section: Polymeric Nanoparticles (Pnps)mentioning

confidence: 99%